Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

You may be eligible if

• DISEASE CHARACTERISTICS:
• Biopsy-proven\* relapsed or refractory lymphoma, including the following:
• * Aggressive lymphoma (closed to accrual as of 2/7/08 except for diffuse large B cell lymphoma, grade III follicular lymphoma, or transformed lymphoma)
• * Transformed lymphoma
• * Diffuse large B-cell lymphoma
• * Mantle cell lymphoma
• * Grade 3 follicular lymphoma
• * Precursor B-cell lymphoblastic leukemia/lymphoma
• * Mediastinal (thymic) large B-cell lymphoma
• * Burkitt's lymphoma/leukemia
• * Precursor T-cell lymphoblastic leukemia/lymphoma
• * Primary cutaneous anaplastic large cell lymphoma
• * Primary systemic type anaplastic large cell lymphoma
• * Indolent lymphoma (closed to accrual as of 8/18/08)
• * Small lymphocytic lymphoma/chronic lymphocytic leukemia
• * Grade 1 or 2 follicular lymphoma
• * Extranodal marginal zone B-cell lymphoma of MALT type
• * Nodal marginal zone B-cell lymphoma
• * Splenic marginal zone B-cell lymphoma
• * Uncommon lymphoma (closed to accrual as of 9/2/08)
• * Unspecified peripheral T-cell lymphoma
• * Anaplastic large cell lymphoma (T and null cell type)
• * Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)
• * Central Nervous System (CNS) lymphoma
• * Post-transplant lymphoproliferative disorder
• * Mycosis fungoides/Sezary syndrome
• * Hodgkin's lymphoma
• * Primary effusion lymphoma
• * Blastic Natural Killer(NK)-cell lymphoma
• * Adult T-cell leukemia/lymphoma
• * Nasal type extranodal NK/T-cell lymphoma
• * Enteropathy type T-cell lymphoma
• * Hepatosplenic T-cell lymphoma
• * Subcutaneous panniculitis-like T-cell lymphoma
• * Angioimmunoblastic T-cell lymphoma
• NOTE: \*Biopsies performed \< 6 months prior to study entry are allowed; biopsy-proven CNS lymphoma (at any time) does not require a re-biopsy in order to be eligible for this study
• Previously treated disease
• * Patients with aggressive lymphoma (closed to accrual as of 8/24/07) OR Hodgkin's lymphoma must have received or be ineligible for potentially curative therapy, including stem cell transplantation
• Measurable disease\*\* by CT scan or MRI, defined by 1 of the following:
• * At least 1 unidimensionally measurable lesion \> 2 cm in diameter
• * Skin lesions may be used if they meet this criterion and are photographed with a ruler
• * More than 5,000/mm³ tumor cells in the blood
• NOTE: \*\*For patients with lymphoplasmacytic lymphoma without measurable lymphadenopathy, measurable disease may be defined by bone marrow lymphoplasmacytosis with \> 10% lymphoplasmacytic cells or aggregates, sheets, lymphocytes, plasma cells, or lymphoplasmacytic cells on bone marrow biopsy AND quantitative Immunoglobulin M(IgM) monoclonal protein \> 1,000 mg/dL
• PATIENT CHARACTERISTICS:
• Eastern Cooperative Oncology Group(ECOG) performance status 0-2
• Life expectancy \> 3 months
• Absolute neutrophil count ≥ 1,000/mm³
• Platelet count ≥ 75,000/mm³
• Hemoglobin ≥ 8 g/dL
• Total bilirubin ≤ 2 times upper limit of normal (ULN) OR direct bilirubin ≤ 1.5 times ULN
• aspartate aminotransferase(AST) ≤ 3 times ULN (5 times ULN if liver involvement is present)
• Creatinine ≤ 2 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Willing to provide blood samples and portion of bone marrow aspirate and biopsy during study participation
• Able to swallow intact study medication tablets
• No other life-threatening illness (unrelated to tumor)
• No serious non-malignant disease (e.g., active infection or other condition) that, in the opinion of the investigator, would preclude study participation
• No other active malignancy requiring treatment or that would preclude study participation
• No known HIV positivity
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• At least 3 weeks since prior myelosuppressive chemotherapy or biologic therapy (unless the patient has recovered from the nadir of the previous treatment)
• More than 3 weeks since prior radiotherapy (unless the acute side effects associated with therapy are resolved)
• Concurrent stable (i.e., not increased within the past month) chronic doses of corticosteroids, with a maximum dose of 20 mg of prednisone per day, is allowed if prescribed for disorders other than lymphoma (e.g., rheumatoid arthritis, polymyalgia rheumatica, adrenal insufficiency, or asthma)
• * Non-escalating doses of steroids at the lowest possible dosing level are allowed for CNS lymphoma
• No other concurrent investigational ancillary therapy
• No other concurrent chemotherapy, immunotherapy, or radiotherapy
• No concurrent participation in any other clinical trial involving a pharmacologic agent (e.g., drugs, biologics, immunotherapy, or gene therapy) for symptom control or therapeutic intent